Biogen Inc

NASDAQ:BIIB   3:59:59 PM EDT
371.90
-2.50 (-0.67%)
4:26:53 PM EDT: $374.93 +3.03 (+0.82%)
Products, Regulatory

Biogen And Eisai Launch Multiple Initiatives To Help Patients With Alzheimer’S Disease Access ADUHELM

Published: 06/07/2021 17:14 GMT
Biogen Inc (BIIB) - Biogen and Eisai Launch Multiple Initiatives to Help Patients With Alzheimer’s Disease Access Aduhelm™.
Biogen Inc - Yearly Cost of Aduhelm at Maintenance Dose (10 Mg/kg) Would Be $56,000.
Biogen - Wholesale Acquisition Cost of Aduhelm is $4,312 per Infusion for a Patient of 74 Kg- Average Weight of a U.S. Patient With Mci/mild Dementia.
Biogen -for Qualified, Commercially Insured Aduhelm Patients, Co-pay, Infusion Cost Assistance Programs May Reduce Out-of-pocket Costs to As Low As $0.
Biogen Inc - Biogen and Eisai Have Committed to Not Increasing Price of Aduhelm for Next Four Years.
Biogen Inc - Cost During First Year of Treatment Will Be Lower Due to Titration Period.